Last reviewed · How we verify
HYCAMTIN, oral capsules
Topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cell death in rapidly dividing cancer cells.
Topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cell death in rapidly dividing cancer cells. Used for Small cell lung cancer (SCLC), relapsed or refractory, Ovarian cancer, relapsed, Cervical cancer.
At a glance
| Generic name | HYCAMTIN, oral capsules |
|---|---|
| Also known as | HYCAMTIN, oral capsules |
| Sponsor | GlaxoSmithKline |
| Drug class | Topoisomerase I inhibitor |
| Target | Topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Topotecan binds to and stabilizes the topoisomerase I-DNA complex, preventing the enzyme from completing its catalytic cycle and leading to accumulation of DNA breaks. This mechanism is particularly effective against cancer cells with high replication rates. The oral capsule formulation allows for convenient at-home administration compared to intravenous alternatives.
Approved indications
- Small cell lung cancer (SCLC), relapsed or refractory
- Ovarian cancer, relapsed
- Cervical cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Alopecia
Key clinical trials
- Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (PHASE2)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan (PHASE1)
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (PHASE2)
- Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (PHASE1)
- Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer (PHASE2)
- Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas (PHASE2)
- Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HYCAMTIN, oral capsules CI brief — competitive landscape report
- HYCAMTIN, oral capsules updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI